Acalatinib/Acalatinib manufacturer

Acalabrutinib/Acalabrutinib is developed by Acerta Pharma. Acerta Pharma is a global biopharmaceutical company focused on R&D and innovation in the field of oncology. The company is committed to developing innovative treatments that improve patients' quality of life and provide better treatment options. Astra Zeneca is a multinational pharmaceutical company headquartered in the United Kingdom. In December 2015, AstraZeneca acquired Acerta Pharma to obtain global development and commercialization rights to acotinib. The acquisition is conditional on the approval of acotinib in the United States and Europe and the establishment of corresponding commercial opportunities.

In the European Union, acotinib is approved as monotherapy or in combination withobinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL). Additionally, it is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. In some countries, acotinib is also indicated for the treatment of adults with mantle cell lymphoma (MCL) and small lymphocytic lymphoma (SLL).

The active substance in acotinibacalabrutinib blocks an enzyme called Bruton's tyrosine kinase, which helps B cells survive and grow. By blocking this enzyme, acotinib is expected to slow down the rate at which cells become cancerous, thereby delaying the progression of cancer. Acotinib is available by prescription only, and treatment should be started and supervised by a doctor experienced in the use of cancer drugs. It is available as capsules for oral administration; the recommended dose is 100 mg twice daily. Treatment can be continued as long as the cancer is under control and there are no unacceptable side effects. If serious side effects occur or certain other medications must be taken, treatment may be interrupted or stopped, or the dose may be adjusted.